William T Hu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9509207/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reporting and social construction of race in Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2022, 18, 865-866.	0.8	1
2	Does limited EMG denervation in early primary lateral sclerosis predict amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 554-561.	1.7	2
3	Cross-species metabolomic analysis of tau- and DDT-related toxicity. , 2022, 1, .		5
4	Cerebral AÎ ² deposition in an AÎ ² -precursor protein-transgenic rhesus monkey. Aging Brain, 2022, 2, 100044.	1.3	2
5	Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes. Dementia and Geriatric Cognitive Disorders Extra, 2021, 11, 19-25.	1.3	6
6	Natural History of "Pure―Primary Lateral Sclerosis. Neurology, 2021, 96, e2231-e2238.	1.1	9
7	A Pilot Randomized Clinical Trial of Adapted Tango to Improve Cognition and Psychosocial Function in African American Women with Family History of Alzheimer's Disease (ACT trial). Cerebral Circulation - Cognition and Behavior, 2021, , 100018.	0.9	1
8	Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease. Nature Communications, 2021, 12, 4001.	12.8	19
9	Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies. Biomolecules, 2021, 11, 1484.	4.0	3
10	Racial differences in biomarkers of Alzheimer's disease and inflammation. Alzheimer's and Dementia, 2021, 17, .	0.8	1
11	Highâ€resolution metabolomic profiling of Alzheimer's disease in plasma. Annals of Clinical and Translational Neurology, 2020, 7, 36-45.	3.7	42
12	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nature Immunology, 2020, 21, 1506-1516.	14.5	563
13	Perspective on the "African American participation in Alzheimer disease research: Effective strategies― workshop, 2018. Alzheimer's and Dementia, 2020, 16, 1734-1744.	0.8	23
14	Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease, Atlanta, Georgia, USA, 2020. Emerging Infectious Diseases, 2020, 26, 2016-2021.	4.3	145
15	Race modifies putamen connectivity in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043597.	0.8	0
16	Localization and protein levels of YKLâ€40 in postmortem brain of frontotemporal dementia and Alzheimer's disease cases. Alzheimer's and Dementia, 2020, 16, e044523.	0.8	0
17	Trust thyself: How older black and white adults consider Alzheimer's disease research participation. Alzheimer's and Dementia, 2020, 16, e044858.	0.8	0
18	A pilot clinical trial of adapted tango to improve negative health impacts in middle aged Africanâ€American women caregivers of persons with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044865.	0.8	1

#	Article	IF	CITATIONS
19	CSF biomarkers for frontotemporal dementia and its pathological subtypes. Alzheimer's and Dementia, 2020, 16, e045851.	0.8	0
20	A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning. Journal of Alzheimer's Disease, 2020, 78, 1381-1392.	2.6	16
21	Race modifies default mode connectivity in Alzheimer's disease. Translational Neurodegeneration, 2020, 9, 8.	8.0	16
22	Herpes simplex virus blocks host transcription termination via the bimodal activities of ICP27. Nature Communications, 2020, 11, 293.	12.8	58
23	Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study. Journal of Alzheimer's Disease, 2020, 75, 109-117.	2.6	15
24	Caution on Plasma Cytokine Findings in 2019 Novel Coronavirus Cases. SSRN Electronic Journal, 2020, , 3555849.	0.4	0
25	Patients with Mild Cognitive Impairment May be Stratified by Advanced Diffusion Metrics and Neurocognitive Testing. Journal of Neuroimaging, 2019, 29, 79-84.	2.0	8
26	LATE to the PART-y. Brain, 2019, 142, e47-e47.	7.6	44
27	Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder. Scientific Reports, 2019, 9, 8733.	3.3	14
28	Interleukin 9 alterations linked to alzheimer disease in african americans. Annals of Neurology, 2019, 86, 407-418.	5.3	42
29	0712 APOE4, But Not Desaturation Index, Is Associated with Dementia Severity In A Memory Clinic Population. Sleep, 2019, 42, A285-A286.	1.1	1
30	CSF Cytokines in Aging, Multiple Sclerosis, and Dementia. Frontiers in Immunology, 2019, 10, 480.	4.8	91
31	O2â€02â€01: DIFFERENT CSF TOTAL AND PHOSPHORYLATED TAU, BUT NOT Aβ, IN OLDER AND YOUNGER AFRIC AMERICANS AND WHITES. Alzheimer's and Dementia, 2019, 15, P535.	CAN 0.8	0
32	Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1815-1826.	2.6	11
33	ICâ€Pâ€039: RACE MODIFIES FUNCTIONAL CONNECTIVITY OF THE DEFAULT MODE NETWORK IN AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P40.	0.8	0
34	NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system. PLoS Neglected Tropical Diseases, 2018, 12, e0007045.	3.0	21
35	P2â€651: A CONSENSUS AROUND GLOBAL RESEARCH PRIORITIES FOR COMMUNITYâ€BASED CARE FROM A STRATEGIC CONVENING MODEL IN SALZBURG, AUSTRIA. Alzheimer's and Dementia, 2018, 14, P992.	0.8	0
36	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 98.	6.2	25

#	Article	IF	CITATIONS
37	Automation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1–42 Peptide in the CSF. Frontiers in Aging Neuroscience, 2018, 10, 253.	3.4	25
38	Novel <scp>CSF</scp> biomarkers to discriminate <scp>FTLD</scp> and its pathological subtypes. Annals of Clinical and Translational Neurology, 2018, 5, 1163-1175.	3.7	20
39	Phosphorylated neurofilament heavy chain: A biomarker of survival for <scp><i>C9ORF</i></scp> <i>72</i> â€associated amyotrophic lateral sclerosis. Annals of Neurology, 2017, 82, 139-146.	5.3	88
40	Poly(GP) proteins are a useful pharmacodynamic marker for <i>C9ORF72</i> -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	179
41	No doubts about dementia advocacy. Lancet Psychiatry,the, 2017, 4, 830.	7.4	3
42	[P4–471]: VALIDATING NONâ€AMYLOID, NONâ€TAU CSF BIOMARKERS FOR ALZHEIMER'S DISEASE IN THE PREâ€SYMPTOMATIC, MCI, AND DEMENTIA STAGES: A MULTIâ€CENTER STUDY. Alzheimer's and Dementia, 2017, 13, P1513.	, 0.8	1
43	[P4–472]: WHAT IS DEMENTIA FRIENDLY? DEVELOPMENT AND VALIDATION OF A NOVEL TOOL TO MEASURE STIGMA ASSOCIATED WITH DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1514.	0.8	0
44	Fear and Uncertainty Do Not Influence Reported Willingness to Undergo Lumbar Punctures in a U.S. Multi-Cultural Cohort. Frontiers in Aging Neuroscience, 2017, 9, 22.	3.4	11
45	Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers. Alzheimer's Research and Therapy, 2017, 9, 88.	6.2	139
46	Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience. Frontiers in Aging Neuroscience, 2016, 8, 296.	3.4	33
47	P4â€123: Resolving Conflicting CSF Biomarker Information in Alzheimer′s Disease. Alzheimer's and Dementia, 2016, 12, P1061.	0.8	0
48	O1â€11â€06: Lower Prevalence of Abnormal CSF Alzheimer's Biomarkers Among African Americans than Caucasians with Normal Cognition or Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P204.	0.8	0
49	Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia. Molecular Neurodegeneration, 2016, 11, 46.	10.8	82
50	Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology, 2016, 87, 1024-1030.	1.1	74
51	CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease. Acta Neuropathologica Communications, 2016, 4, 14.	5.2	35
52	Knowledge and Attitudes in Alzheimer's Disease in a Cohort of Older African Americans and Caucasians. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 361-367.	1.9	10
53	CSF betaâ€amyloid 1–42 – what are we measuring in Alzheimer's disease?. Annals of Clinical and Translational Neurology, 2015, 2, 131-139.	3.7	34
54	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	7.6	109

#	Article	IF	CITATIONS
55	Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	2.4	35
56	Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 442.	9.0	74
57	The future of bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 115-131.	0.8	250
58	Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nature Medicine, 2014, 20, 1254-1262.	30.7	367
59	Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential. Current Alzheimer Research, 2014, 11, 165-174.	1.4	54
60	Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on?. Acta Neuropathologica, 2013, 126, 625-629.	7.7	5
61	Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 9-12.	0.6	55
62	Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 21.	6.2	124
63	The advantages of frontotemporal degeneration drug development (partÂ2Âof frontotemporal) Tj ETQq1 1 0.7	784314 rgB 0.8	T /Qyerlock 1
64	From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. International Review of Psychiatry, 2013, 25, 210-220.	2.8	13
65	Reduced CSF p-Tau ₁₈₁ to Tau ratio is a biomarker for FTLD-TDP. Neurology, 2013, 81, 1945-1952.	1.1	100
66	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2013, 80, 690-691.	1.1	5
67	Behavior Matters—Cognitive Predictors of Survival in Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e57584.	2.5	61
68	Plasma biomarkers of depressive symptoms in older adults. Translational Psychiatry, 2012, 2, e65-e65.	4.8	48
69	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2012, 79, 897-905.	1.1	208
70	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathologica, 2012, 124, 23-35.	7.7	161
71	Biomarkers in frontotemporal lobar degenerations—Progress and challenges. Progress in Neurobiology, 2011, 95, 636-648.	5.7	36
72	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathologica, 2011, 121, 373-380.	7.7	102

#	Article	IF	CITATIONS
73	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Annals of Neurology, 2011, 69, 655-663.	5.3	126
74	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. Archives of Neurology, 2011, 68, 488.	4.5	108
75	PATIENT MANAGEMENT PROBLEM. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 153-164.	0.8	0
76	Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathologica, 2010, 119, 669-678.	7.7	164
77	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathologica, 2010, 120, 385-399.	7.7	79
78	Anatomical differences between CBSâ€corticobasal degeneration and CBSâ€Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	3.9	71
79	Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology, 2010, 75, 2079-2086.	1.1	89
80	Distinct cerebral perfusion patterns in FTLD and AD. Neurology, 2010, 75, 881-888.	1.1	153
81	Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology, 2010, 75, 595-602.	1.1	98
82	Extrapyramidal reaction to ondansetron and propofol. Movement Disorders, 2009, 24, 312-313.	3.9	10
83	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 2009, 24, 1375-1379.	3.9	105
84	TDP-43 and frontotemporal dementia. Current Neurology and Neuroscience Reports, 2009, 9, 353-358.	4.2	19
85	Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease. Archives of Neurology, 2009, 66, 1359-64.	4.5	83
86	Amyloid-beta alters trafficking of internalized acetylcholinesterase and dextran. International Journal of Physiology, Pathophysiology and Pharmacology, 2009, 1, 15-24.	0.8	0
87	Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathologica, 2008, 116, 215-220.	7.7	124
88	Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology, 2008, 70, 1850-1857.	1.1	220
89	Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology, 2008, 70, 25-34.	1.1	143
90	Long-Term Follow-up after Treatment of Rabies by Induction of Coma. New England Journal of Medicine, 2007, 357, 945-946.	27.0	70

#	Article	IF	CITATIONS
91	Clinical Features of Pathologic Subtypes of Behavioral-Variant Frontotemporal Dementia. Archives of Neurology, 2007, 64, 1611.	4.5	35
92	Ornithine Transcarbamylase Deficiency Presenting as Encephalopathy During Adulthood Following Bariatric Surgery. Archives of Neurology, 2007, 64, 126.	4.5	49
93	Clinical Features and Survival of 3R and 4R Tauopathies Presenting as Behavioral Variant Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2007, 21, S39-S43.	1.3	23
94	Sudden Coma Due to Acute Bilateral M1 Occlusion. Mayo Clinic Proceedings, 2007, 82, 1155.	3.0	10
95	Childhood obesity among Head Start enrollees in southeastern Minnesota: prevalence and risk factors. Ethnicity and Disease, 2007, 17, 23-8.	2.3	16
96	Cognitive Impairment and Celiac Disease. Archives of Neurology, 2006, 63, 1440.	4.5	143
97	MRI findings of rapidly progressive ophthalmoplegia and blindness in mucormycosis. Neurology, 2006, 66, E40-E40.	1.1	2
98	MRI correlates of alien leg-like phenomenon in corticobasal degeneration. Movement Disorders, 2005, 20, 870-873.	3.9	21
99	75-Year-Old Man With Progressive Shortness of Breath on Exertion. Mayo Clinic Proceedings, 2005, 80, 1651-1654.	3.0	0
100	Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. Journal of Neurochemistry, 2004, 86, 470-478.	3.9	73
101	Neuroimaging of other dementing disorders. , 0, , 371-394.		0